Search results for " papillomavirus"

showing 10 items of 108 documents

Use of Interferon-Alpha in Recurrent Respiratory Papillomatosis: 20-Year Follow-up

2005

Objectives: The aim of this study was analysis of the results of use of interferon-α (IFN-α) in patients with recurrent respiratory papillomatosis (RRP) and correlation of the results with human papillomavirus (HPV) type. Methods: A multicenter prospective series (42 patients from 22 hospitals) yielded 20 years of follow-up of patients with RRP and HPV typing who were treated with IFN-α in doses of 3 MU/m2 3 times per week. Results: During long-term follow-up (mean ± SD, 172 ± 36.8 months), the rate of event-free survival evaluated by Kaplan-Meier analysis was 42.8%, and the overall survival rate was 82.6%. The HPV typing revealed an association of HPV 11 with a more aggressive disease cour…

AdultMalemedicine.medical_specialtyAdolescentAlpha interferonAntineoplastic AgentsInjections IntramuscularDisease-Free Survival03 medical and health sciences0302 clinical medicineInternal medicinemedicineAdjuvant therapyHumansDNA Probes HPVProspective StudiesHuman papillomavirusChild030223 otorhinolaryngologyProspective cohort studyLaryngeal NeoplasmsPapillomaviridaeInterferon alfaPapillomabusiness.industryIncidence (epidemiology)InfantInterferon-alphaGeneral MedicineMiddle AgedSurgeryClinical trialTreatment OutcomeOtorhinolaryngologyChild Preschool030220 oncology & carcinogenesisFemaleNeoplasm Recurrence LocalRecurrent Respiratory PapillomatosisbusinessFollow-Up Studiesmedicine.drugAnnals of Otology, Rhinology & Laryngology
researchProduct

Immunization Campaigns and Strategies against Human Papillomavirus in Italy: The Results of a Survey to Regional and Local Health Units Representativ…

2019

Objective. The study aimed to assess the impact of HPV immunization campaigns organizational aspects, the characteristics of immunization program (vaccination targets and type of offer), and communicative strategies adopted by four Italian administrative regions on vaccination coverage observed. Methods. From November 2017 to March 2018, regional and Local Health Units (LHUs) representatives were invited to complete an online survey including 54 questions evaluating vaccination invite systems, access systems to vaccination centres, reminder and recall systems, and adverse events surveillance. An overall descriptive analysis was conducted. Since observed vaccine coverage (VC) obtained in fem…

AdultMalemedicine.medical_specialtyArticle SubjectImmunization registryMEDLINElcsh:MedicineGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicine030225 pediatricsHealth careHumansMedicinePapillomavirus Vaccines030212 general & internal medicineHuman papillomavirusSurveyPapillomaviridaeCopaymentGeneral Immunology and MicrobiologyDescriptive statisticsImmunization Campaigns and StrategieImmunization Programsbusiness.industryPapillomavirus InfectionsVaccinationlcsh:RAdult; Female; Humans; Immunization Programs; Italy; Male; Papillomaviridae; Papillomavirus Infections; Papillomavirus Vaccines; VaccinationGeneral MedicineVaccinationHuman PapillomaviruItalyImmunizationFamily medicineFemalebusinessResearch ArticleBioMed Research International
researchProduct

Determinants of high-grade anal intraepithelial lesions in HIV-positive MSM.

2018

Objective - To assess determinants for histologically proven high-grade anal intraepithelial lesions (hHSIL) in HIV-positive men who have sex with men (MSM), a population at high-risk of HPV-related anal cancer. Design - APACHES is a prospective study of anal HPV and related-lesions in 513 HIV-positive MSM aged at least 35 years in six centres across France. Methods - At baseline, participants underwent high-resolution anoscopy (HRA) with biopsy of suspicious lesions, preceded by anal swabs for liquid-based cytology, p16/Ki67 immunostaining, and HPV DNA. hHSIL diagnosis was established by histopathological review panel consensus, and determinants assessed by logistic regression. Results - B…

AdultMalemedicine.medical_specialtyBiopsyImmunologyPopulationHIV InfectionsMen who have sex with men03 medical and health sciences0302 clinical medicineCytologyInternal medicineBiopsymedicinePrevalenceImmunology and AllergyAnal cancerHumans030212 general & internal medicineProspective StudiesHomosexuality MaleProspective cohort studyeducationAgededucation.field_of_studyHuman papillomavirus 16medicine.diagnostic_testbusiness.industryPapillomavirus InfectionsAnoscopyMiddle Agedmedicine.diseaseAnus Neoplasms3. Good healthInfectious Diseases030220 oncology & carcinogenesisFemaleFranceSquamous Intraepithelial Lesions of the CervixbusinessAscusAIDS (London, England)
researchProduct

Successful treatment of condylomata acuminata at the urethral meatus with high-dose ingenol mebutate gel: Report of two cases

2019

Condylomata acuminata (CA), or anogenital warts, is the most common sexually transmitted infection. Treatments for CA generally have suboptimal recurrence rates, which results in a need for repeated treatments and adds to the already negative impact on the patients’ quality of life. CA can present at the urethral meatus, which is a particularly challenging anatomic location from a therapeutic perspective. We report two cases of CA at the urethral meatus successfully treated with topical application of high-dose ingenol mebutate gel.

AdultMalemedicine.medical_specialtyIngenol Mebutate GelPenile DiseasesAdolescentTreatment outcomeIngenol mebutateDermatologyGenital warts03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemedicineHumansPharmacology (medical)030212 general & internal medicineHuman papillomavirusAnatomic LocationPapillomaviridaeUrethral meatus030505 public healthbusiness.industryPublic Health Environmental and Occupational Healthvirus diseasesmedicine.diseaseDermatologyTreatment OutcomeInfectious DiseaseschemistryCondylomata AcuminataDiterpenes0305 other medical sciencebusinessGelsInternational Journal of STD & AIDS
researchProduct

Human papillomavirus is commonly present in psoriatic skin and normal skin samples from healthy subjects

2007

Letter to editor No abstract

AdultMalemedicine.medical_specialtybusiness.industryPapillomavirus InfectionsHealthy subjectsDermatologyMiddle AgedBiochemistryDermatologyPsoriatic skinPrevalencemedicineHumansPsoriasisFemaleHuman papillomavirusNormal skinbusinessMolecular BiologySkinJournal of Dermatological Science
researchProduct

Immunogenicity and safety of human papillomavirus-16/18 AS04-adjuvanted vaccine administered according to an alternative dosing schedule compared wit…

2011

BACKGROUND: The human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine is immunogenic, has a clinically acceptable safety profile, and prevents incident and persistent HPV-16/18 infection and cervical precancerous lesions. This study (NCT00552279) evaluated the vaccine when administered according to an alternative dosing schedule (0-1-12 months) compared with the standard dosing schedule (0-1-6 months). METHODS: The study was of randomized open design and was conducted at multiple centers in Europe. Healthy women aged 15 to 25 years were randomized (1:1) to receive HPV-16/18 vaccine according to the standard schedule at months 0, 1, and 6 (n = 401) or an alternative schedule at months 0, …

AdultMicrobiology (medical)medicine.medical_specialtyScheduleAdolescentImmunization SecondaryEnzyme-Linked Immunosorbent AssayAntibodies Virallaw.inventionYoung AdultAdjuvants ImmunologicRandomized controlled triallawInternal medicinemedicineHumansPapillomavirus VaccinesDosingHuman papillomavirusYoung adultbusiness.industryImmunogenicityhuman papillomavirus human papillomavirus vaccines adolescent immunology alternative dosing scheduleVaccinationvirus diseasesSettore MED/40 - Ginecologia E Ostetriciafemale genital diseases and pregnancy complicationsEuropeSafety profileInfectious DiseasesImmunizationPediatrics Perinatology and Child HealthImmunologyFemalebusiness
researchProduct

Human papillomavirus antibody responses among patients with incident cervical carcinoma

1997

The human papillomavirus (HPV) is recognized as a major cause of cervical cancer precursor lesions. HPV serology is a key method in the continuing elucidation of the importance of HPV exposure for cancer development and in predicting HPV-associated diseases. To extend previous HPV serological studies on cervical cancer, serum samples from a consecutive series of 216 women with incident untreated cervical carcinoma and 243 age- and sex-matched healthy blood donors were evaluated for the presence of antibodies against HPV capsids, a marker of past or present HPV exposure, as well as against several cervical cancer-associated defined HPV epitopes. Among the capsid antibody responses, HPV type …

AdultMolecular Sequence DataUterine Cervical NeoplasmsAntibodies ViralKlinikai orvostudományokEpitopeSerologyEpitopesCapsidRisk FactorsVirologyCarcinomamedicineHumansAmino Acid SequenceRisk factorAntigens ViralPapillomaviridaeAgedAged 80 and overCervical cancerbiologybusiness.industryPapillomavirus Infectionsvirus diseasesOrvostudományokMiddle Agedmedicine.diseaseVirologyfemale genital diseases and pregnancy complicationsTumor Virus InfectionsInfectious DiseasesCase-Control StudiesImmunologybiology.proteinFemaleHuman Papillomavirus AntibodyViral diseaseAntibodybusiness
researchProduct

Telomere length in leukocytes and cervical smears of women with high-risk human papillomavirus (HR HPV) infection

2019

Objective: Persistent high-risk HPV (HR HPV) infection leads to the development of squamous intraepithelial lesions, which in turn may progress to cervical cancer. Telomere elongation or shortening may indicate a carcinogenesis process. In the present study, we analyzed telomere length from blood and cervical smears of women without and with high-risk HPV infection. Materials and methods: Telomere length was quantified by real-time PCR in blood and cervical smears from 48 women with high-risk HPV infection and HGSIL or LGSIL, 29 women HR-HPV positive without SIL, and 11 HPV-negative women. Results: No correlation was found between age and telomere length in blood and cervical smears. Women …

AdultOncologyHuman papillomavirusmedicine.medical_specialtyUterine Cervical NeoplasmsCervix Uterimedicine.disease_causelcsh:Gynecology and obstetricsRisk Assessment03 medical and health sciences0302 clinical medicineInternal medicineLeukocytesHumansMedicineHuman papillomavirusPapillomaviridaelcsh:RG1-991Early Detection of CancerVaginal SmearsCervical cancer030219 obstetrics & reproductive medicinebusiness.industryPapillomavirus InfectionsHPV infectionvirus diseasesObstetrics and GynecologyCervical cellsLeukocyteTelomeremedicine.diseaseCervical smearsfemale genital diseases and pregnancy complicationsTelomereCervical smearCase-Control StudiesFemalebusinessCarcinogenesisTelomere elongationPapanicolaou TestTaiwanese Journal of Obstetrics and Gynecology
researchProduct

Proliferative verrucous vs conventional leukoplakia: no significantly increased risk of HPV infection

2004

Proliferative verrucous leukoplakia (PVL) is a very aggressive form of oral leukoplakia (OL) with high morbidity and mortality rates, hypothesised to be linked to HPV infection. This study aimed to determine the presence of HPV DNA in PVL in comparison with OL, and in relation to social-demographical variables (age, gender, smoking and drinking habits) in an Italian multi-centric hospital-based study. The study group consisted of 58 cases of PVL and 90 cases of OL as controls (47 homogeneous (H) and 43 non-homogeneous (non-H) form), both recruited from four Italian cohorts. HPV DNA was identified in exfoliated mucosal cells by nested PCR (nPCR) with MY09/MY11 and GP5+/GP6+ primer pairs and …

AdultOralMaleCancer Researchmedicine.medical_specialtyGenotypeGastroenterologyVirusVerrucousRisk FactorsInternal medicineGenotypemedicineCarcinomaHumansCarcinoma VerrucousViralPapillomaviridaeRisk factorPapillomaviridaeLeukoplakiaAdult; Carcinoma; Verrucous; DNA; Viral; Female; Genotype; Humans; Leukoplakia; Oral; Male; Middle Aged; Papillomaviridae; Papillomavirus Infections; Risk Factors; SmokingbiologyCarcinomaPapillomavirus InfectionsSmokingHPV infectionvirus diseasesDNAMiddle Agedmedicine.diseasebiology.organism_classificationVirologyfemale genital diseases and pregnancy complicationsOncologyDNA ViralFemaleOral SurgeryLeukoplakia OralNested polymerase chain reactionLeukoplakia
researchProduct

Impact of a new carrageenan-based vaginal microbicide in a female population with genital HPV-infection: First experimental results

2019

OBJECTIVE: The objective of this study was to assess safety, satisfaction, and anti- viral effect of a new carrageenan-based vaginal microbicide in a population of fertile female patients with genital human papillomavirus (HPV) infection. PATIENTS AND METHODS: Forty healthy and sexually active women aged 18-45 years with genital HPV infection were enrolled. Each subject was treated with a gel formulated with 0.02% carrageenan and Propionibacterium extract (CGP) (Carvir, Depofarma SpA, Mogliano Veneto, Treviso, Italy). The subjects were evaluated at baseline, after the I cycle of therapy and after the II cycle. At final status, treatment acceptability and satisfaction were evaluated using a …

AdultSettore MED/07 - Microbiologia E Microbiologia ClinicaHPVAdolescentSocio-culturaleMicrobicideCarrageenanCarrageenan Papillomavirus Microbicide Female population HPV.Young AdultAnti-Infective AgentsChondrusHumansProspective StudiesCarrageenan Papillomavirus Microbicide Female population HPVPapillomaviridaeFemale populationPapillomavirus InfectionsMiddle AgedPapillomavirusSeaweedAdministration IntravaginalTreatment OutcomeColposcopyPatient SatisfactionCase-Control StudiesDNA ViralVaginaVaginal Creams Foams and JelliesFemaleFollow-Up Studies
researchProduct